Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • Nelarabine Injection
  • Pipeline
    • SH-105
    • SH-110
    • SH-114
  • News
    • Company Updates
    • Media
  • Contact

Media

FDA Approves Nelarabine Injection for T-cell Leukemia and Lymphoma

March 27th 2023

Read More

US FDA approves Shorla’s oncology drug for T-cell leukaemia

March 20th 2023

Read More

Shorla wins FDA approval for leukaemia drug

March 20th 2023

Read More

Irish-founded Shorla Oncology secures FDA approval for leukaemia drug

March 9th 2023

Read More

Improve Oncology Drug Shortages with A More Reliable Supply Source

October 13th 2022October 10th 2022

Read More

Our CEO on Biocentury’s Bio€quity Europe podcast

May 25th 2022May 18th 2022

Read More

3 Keys To A Successful Biotech Launch

February 28th 2022February 1st 2022

Read More

Shorla: making women’s and children’s cancer drugs more accessible

March 7th 2022December 22nd 2021

Read More

PharmaVoice Women of the Week – Podcast

March 7th 2022June 2nd 2021

Read More

Older posts
Page1 Page2 Page3

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

 

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP
PRIVACY POLICY
Company number: 618033
©SHORLA ONCOLOGY® 2022

© 2023 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • Nelarabine Injection
  • Pipeline
    • SH-105
    • SH-110
    • SH-114
  • News
    • Company Updates
    • Media
  • Contact